NCT05985135Withdrawn
Impact of Insulin Deprivation and Hyperglycemia on Plasma Protein Synthesis in People With Type 1 Diabetes Mellitus
Impact of Insulin Deprivation and Hyperglycemia on Plasma Protein Synthesis in People With Type 1 Diabetes Mellitus and Diabetes After Total Pancreatectomy
Source: ClinicalTrials.gov · Last updated 5 Aug 2026
Brief summary (registry, in English)
This research is being done to better understand how insulin effects muscle, blood, and the body in people with Type 1 Diabetes.
- Status (registry)
- Withdrawn
- Study type
- Interventional
- Enrollment
- 0 (actual)
- First submitted
- 2 Aug 2023
- Start date
- 1 Jun 2026
- Primary completion date
- 31 Jul 2026
- Lead sponsor
- Mayo Clinic
- Diseases
- Type 1 diabetes
- NCT number
- NCT05985135
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other illness
- Celiac disease.
- Reported history of illicit substance use.
- History of active cardiovascular, cerebrovascular, or peripheral vascular disease.
- Dementia or any other neurologic disease.
- Uncontrolled psychiatric disease.
- Celiac disease.
- Reported history of illicit substance use.
- History of active cardiovascular, cerebrovascular, or peripheral vascular disease.
- Dementia or any other neurologic disease.
- Uncontrolled psychiatric disease.
Lab values
- Active renal disease evidenced by estimated glomerular filtration rate (GFR) < 50 mL/min/1.73 m\^2.
- Hemoglobin A1c > 9.0%.
- Type 2 Diabetes Mellitus (T2DM), or impaired fasting glucose.
- Active renal disease evidenced by estimated GFR < 50 mL/min/1.73 m\^2.
- T2DM, or impaired fasting glucose.
Other
- BMI < 20 or > 32 kg/m\^2.
- Pregnancy.
- Smoking.
- Severe peripheral or autonomic neuropathy.
- Any learning disability.
- Anemia.
- Thyroid-stimulating hormone (TSH) ≥ 7 or TSH ≤ 7 and free T4 ≤ 0.9.
- Detectable C peptide.
- BMI < 20 or > 32 kg/m\^2.
- Pregnancy.
- Smoking.
- Severe peripheral or autonomic neuropathy.
- Any learning disability.
- Anemia.
- TSH ≥ 7 or TSH ≤ 7 and free T4 ≤ 0.9.
Who the study is looking for
- Able to provide written consent.
- Able to provide written consent.
- T1DM treated with continuous subcutaneous insulin infusion (CSII) or multiple daily injections (MDI) (not Degludec).
Age in the registry: 18 years to 70 years · Sex: All · Accepts healthy volunteers
Sites (1)
Sites in registry order. Save your city in your profile to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Mayo Clinic Coordinator of this site? Confirm its status | Rochester | United States | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.